Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of low- and high-titer JVC-001 in healthy Japanese children aged 12 to under 24 months
jRCT2080225025Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of measles, mumps and rubella vaccine (live) in measles, mumps and rubella (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Immunogenicity on Day 43 and Safety and tolerability after vaccination. Started Jan 2020; status: completed.
02
Drugs
measles, mumps and rubella vaccine (live)
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on jRCT2080225025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225025.